Discounted Cash Flow
Castle Biosciences Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $22.8m | $-6.4m | $-12.6m | -27.9% | $-5.33 |
| 2019 | $51.9m (127.6%) | $5.3m (182.9%) | $6.1m (148.3%) | 10.2% (136.4%) | $0.35 (106.6%) |
| 2020 | $62.6m (20.8%) | $-10.3m (-294.9%) | $5.1m (-15.9%) | -16.4% (-261.3%) | $-0.54 (-254.3%) |
| 2021 | $94.1m (50.2%) | $-31.3m (-204.3%) | $-22.5m (-539.3%) | -33.3% (-102.6%) | $-1.24 (-129.6%) |
| 2022 | $137.0m (45.7%) | $-67.1m (-114.6%) | $-47.3m (-110.5%) | -49.0% (-47.3%) | $-2.58 (-108.1%) |
| 2023 | $219.8m (60.4%) | $-57.5m (14.4%) | $-19.2m (59.3%) | -26.1% (46.6%) | $-2.14 (17.1%) |
| 2024 | $332.1m (51.1%) | $18.2m (131.7%) | $36.5m (289.8%) | 5.5% (121.0%) | $0.66 (130.8%) |
| 2025 | $344.2m (3.7%) | $-24.2m (-232.4%) | $28.3m (-22.5%) | -7.0% (-227.7%) | $-0.83 (-225.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.